Literature DB >> 10725751

Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes.

R J Harris1, A R Pettitt, C Schmutz, P D Sherrington, M Zuzel, J C Cawley, S D Griffiths.   

Abstract

The role of GM-CSF in B cell (patho)physiology is unclear. Although B cells can respond to GM-CSF, there is controversy concerning the extent to which various resting and activated B cell types can themselves produce this cytokine, and the possibility that it can function in an autocrine fashion has not previously been considered. The aim of the present study was to address these issues using hairy cells (HCs) and chronic lymphocytic leukemia cells, two intrinsically activated mature malignant B cell types (with activation being more uniform and more pronounced in HCs). Normal B cells were used for comparison. Using a number of techniques, we demonstrated the constitutive production of GM-CSF by all three cell types and showed that the cytokine was biologically active. GM-CSF mRNA and protein were increased after cell activation by PMA, and constitutive production of the cytokine was highest in HCs, suggesting that the level of GM-CSF production is influenced by cell activation. Because GM-CSF is known to be antiapoptotic for myeloid cells, we used blocking anti-GM-CSF Abs to examine the contribution of autocrinely produced cytokine to cell survival. The Abs produced marked reduction in the in vitro survival of HCs, chronic lymphocytic leukemia cells, and normal B cells by promoting apoptosis. Taken together, these findings suggest that, in combination with other known rescue factors, autocrinely produced GM-CSF may contribute to normal and malignant B cell survival in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725751     DOI: 10.4049/jimmunol.164.7.3887

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Innate response activator B cells protect against microbial sepsis.

Authors:  Philipp J Rauch; Aleksey Chudnovskiy; Clinton S Robbins; Georg F Weber; Martin Etzrodt; Ingo Hilgendorf; Elizabeth Tiglao; Jose-Luiz Figueiredo; Yoshiko Iwamoto; Igor Theurl; Rostic Gorbatov; Michael T Waring; Adam T Chicoine; Majd Mouded; Mikael J Pittet; Matthias Nahrendorf; Ralph Weissleder; Filip K Swirski
Journal:  Science       Date:  2012-01-12       Impact factor: 47.728

Review 2.  GM-CSF: An immune modulatory cytokine that can suppress autoimmunity.

Authors:  Palash Bhattacharya; Muthusamy Thiruppathi; Hatem A Elshabrawy; Khaled Alharshawi; Prabhakaran Kumar; Bellur S Prabhakar
Journal:  Cytokine       Date:  2015-06-22       Impact factor: 3.861

Review 3.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.

Authors:  Anil Kumar; Adeleh Taghi Khani; Ashly Sanchez Ortiz; Srividya Swaminathan
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

4.  GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.

Authors:  Hemanth K Potluri; Tun L Ng; Michael A Newton; Douglas G McNeel
Journal:  Cancer Immunol Immunother       Date:  2022-02-08       Impact factor: 6.630

5.  High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease.

Authors:  A Sergeeva; Y Ono; R Rios; J J Molldrem
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

6.  Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models.

Authors:  P F Forde; L J Hall; M de Kruijf; M G Bourke; T Doddy; M Sadadcharam; D M Soden
Journal:  Gene Ther       Date:  2014-11-06       Impact factor: 5.250

Review 7.  Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis.

Authors:  Jehan Aram; Anna Francis; Radu Tanasescu; Cris S Constantinescu
Journal:  Neurol Ther       Date:  2018-12-01

8.  Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias.

Authors:  Ying Yan; Eric A Wieman; Xiuqin Guan; Ann A Jakubowski; Peter G Steinherz; Richard J O'Reilly
Journal:  J Hematol Oncol       Date:  2009-12-29       Impact factor: 17.388

Review 9.  GM-CSF: Orchestrating the Pulmonary Response to Infection.

Authors:  Thomas S McCormick; Rana B Hejal; Luis O Leal; Mahmoud A Ghannoum
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.